FDA Complete Response Slows Down, But Won't Stop, Lundbeck's Serdolect
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency comes to same conclusion as advisory committee: the risky schizophrenia drug could get approved if an appropriate patient group is identified.